Brief: ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules For Advanced Cancer Pain Management
05/12/2023 12:35
Dec 5 (Reuters) - ZYUS Life Sciences Corp ZYUS.V :
* ZYUS LIFE SCIENCES CORPORATION ANNOUNCES PHASE 2 CLINICAL
TRIAL
EVALUATING TRICHOMYLIN® SOFTGEL CAPSULES FOR ADVANCED CANCER
PAIN MANAGEMENT
* ZYUS LIFE SCIENCES CORP - EVALUATING EFFICACY, SAFETY, AND
TOLERABILITY IN PATIENTS WITH MODERATE TO SEVERE CANCER-RELATED
PAIN
Source text for Eikon: ID:nBw41phD5a
Further company coverage: ZYUS.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyus Life Sciences
See all newsBrief: Zyus Life Sciences Announces Strategic Realignment To Prioritize Drug Development
Brief: Zyus Life Sciences Reports Preliminary Results From Ongoing Phase 2A Utopia-1 Trial
Brief: ZYUS Life Sciences Provides Update On Clinical Trial Progress And Unit Private Placement
Brief: Zyus Closes First Tranche Of Unit Offering, Issues Warrants Under Loan Agreements And Note Amendment
Brief: Zyus Life Sciences Corporation Announces Closing Of Additional Secured Loan